BACKGROUND: Detection of melanoma cells in circulation may be important in assessing tumor progression. The objective of this study was to develop a specific, reliable multimarker quantitative real-time reverse transcription-PCR (qRT) assay for detecting melanoma cells in patients' blood. METHODS: We developed qRT assays for the mRNA of four melanoma-associated markers: MART-1, GalNAc-T, PAX-3, and MAGE-A3. In optimization studies, we tested 17 melanoma cell lines and 49 peripheral blood leukocyte (PBL) samples from volunteers. We performed RNA and melanoma cell dilution studies to assess the detection limits and imprecision of the assays. We measured the mRNAs in blood specimens from 94 melanoma patients [American Joint Committee on Cancer (AJCC) stage I, n = 20; II, n = 20; III, n = 32; IV, n = 22]. RESULTS: All markers were frequently detected in melanoma cell lines, whereas none of the markers was detected in PBLs from volunteers. The qRT assay could detect 1 melanoma cell in 10(7) PBLs in the melanoma cell-dilution studies. Markers were detected in 15%, 30%, 75%, and 86% of melanoma patients with AJCC stage I, II, III, and IV disease, respectively. The number of positive markers and AJCC stage were significantly correlated (Spearman correlation coefficient = 0.58; P < 0.0001). CONCLUSIONS: Multimarker qRT can detect circulating melanoma cells in blood. Measurement of the studied molecular markers in blood may be useful in detection of metastasis and monitoring treatment response of melanoma patients.
BACKGROUND: Detection of melanoma cells in circulation may be important in assessing tumor progression. The objective of this study was to develop a specific, reliable multimarker quantitative real-time reverse transcription-PCR (qRT) assay for detecting melanoma cells in patients' blood. METHODS: We developed qRT assays for the mRNA of four melanoma-associated markers: MART-1, GalNAc-T, PAX-3, and MAGE-A3. In optimization studies, we tested 17 melanoma cell lines and 49 peripheral blood leukocyte (PBL) samples from volunteers. We performed RNA and melanoma cell dilution studies to assess the detection limits and imprecision of the assays. We measured the mRNAs in blood specimens from 94 melanomapatients [American Joint Committee on Cancer (AJCC) stage I, n = 20; II, n = 20; III, n = 32; IV, n = 22]. RESULTS: All markers were frequently detected in melanoma cell lines, whereas none of the markers was detected in PBLs from volunteers. The qRT assay could detect 1 melanoma cell in 10(7) PBLs in the melanoma cell-dilution studies. Markers were detected in 15%, 30%, 75%, and 86% of melanomapatients with AJCC stage I, II, III, and IV disease, respectively. The number of positive markers and AJCC stage were significantly correlated (Spearman correlation coefficient = 0.58; P < 0.0001). CONCLUSIONS: Multimarker qRT can detect circulating melanoma cells in blood. Measurement of the studied molecular markers in blood may be useful in detection of metastasis and monitoring treatment response of melanomapatients.
Authors: Megan K Baker; Kaidi Mikhitarian; Walid Osta; Kathi Callahan; Rana Hoda; Frank Brescia; Rayna Kneuper-Hall; Michael Mitas; David J Cole; William E Gillanders Journal: Clin Cancer Res Date: 2003-10-15 Impact factor: 12.531
Authors: C Walther; J L Guenet; D Simon; U Deutsch; B Jostes; M D Goulding; D Plachov; R Balling; P Gruss Journal: Genomics Date: 1991-10 Impact factor: 5.736
Authors: Charles M Balch; Antonio C Buzaid; Seng-Jaw Soong; Michael B Atkins; Natale Cascinelli; Daniel G Coit; Irvin D Fleming; Jeffrey E Gershenwald; Alan Houghton; John M Kirkwood; Kelly M McMasters; Martin F Mihm; Donald L Morton; Douglas S Reintgen; Merrick I Ross; Arthur Sober; John A Thompson; John F Thompson Journal: Semin Surg Oncol Date: 2003
Authors: Robert A Wascher; Donald L Morton; Christine Kuo; Robert M Elashoff; He-Jing Wang; Mehri Gerami; Dave S B Hoon Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: Aliki Stathopoulou; Anna Gizi; Maria Perraki; Stella Apostolaki; Nikos Malamos; Dimitris Mavroudis; Vassilis Georgoulias; Evi S Lianidou Journal: Clin Cancer Res Date: 2003-11-01 Impact factor: 12.531
Authors: Kazuo Koyanagi; Steven J O'Day; Rene Gonzalez; Karl Lewis; William A Robinson; Thomas T Amatruda; He-Jing Wang; Robert M Elashoff; Hiroya Takeuchi; Naoyuki Umetani; Dave S B Hoon Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Sojun Hoshimoto; Mark B Faries; Donald L Morton; Tatsushi Shingai; Christine Kuo; He-Jing Wang; Robert Elashoff; Nicola Mozzillo; Mark C Kelley; John F Thompson; Jeffrey E Lee; Dave S B Hoon Journal: Ann Surg Date: 2012-02 Impact factor: 12.969
Authors: Kazuo Koyanagi; Takuji Mori; Steven J O'Day; Steve R Martinez; He-Jing Wang; Dave S B Hoon Journal: Cancer Res Date: 2006-06-15 Impact factor: 12.701
Authors: Minoru Kitago; Kazuo Koyanagi; Takeshi Nakamura; Yasufumi Goto; Mark Faries; Steven J O'Day; Donald L Morton; Soldano Ferrone; Dave S B Hoon Journal: Clin Chem Date: 2009-02-20 Impact factor: 8.327
Authors: Melody J Xu; Jay F Dorsey; Ravi Amaravadi; Giorgos Karakousis; Charles B Simone; Xiaowei Xu; Wei Xu; Erica L Carpenter; Lynn Schuchter; Gary D Kao Journal: Oncologist Date: 2015-11-27